학술논문
Baricitinib for atopic dermatitis patients who responded inadequately to dupilumab treatment: First daily practice results
Document Type
article
Source
JEADV Clinical Practice, Vol 1, Iss 4, Pp 364-371 (2022)
Subject
Language
English
ISSN
2768-6566
Abstract
Abstract Background Baricitinib is the first JAK inhibitor registered for the treatment of moderate‐to‐severe atopic dermatitis (AD). Efficacy and safety were shown in clinical trials, but daily practice data is sparse. Objectives To evaluate the effectiveness and safety of baricitinib treatment in daily practice in AD patients who have inadequately responded to dupilumab. Methods In this prospective observational cohort study, AD patients who failed dupilumab treatment and started baricitinib treatment in context of standard care at the Erasmus MC (the Netherlands) were included. We analysed physician‐reported scores and patient‐reported outcome measure scores (PROMs). Results Twenty‐five patients were included. Baricitinib treatment resulted in significant improvement of Eczema Area and Severity Index (EASI) scores and PROMs. Seven patients showed a good and sustained response (EASI50), eight patients showed no response (